Search

Your search keyword '"Calvo-Alen J"' showing total 101 results

Search Constraints

Start Over You searched for: Author "Calvo-Alen J" Remove constraint Author: "Calvo-Alen J"
101 results on '"Calvo-Alen J"'

Search Results

1. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

2. Aportaciones del registro de lupus de la Sociedad Española de Reumatología (RELESSER) al conocimiento del lupus eritematoso sistémico en España

3. AB1677 VALIDATION ANALYSIS OF THE PHYSICIAN GLOBAL ASSESSMENT (PGA) SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS INCLUDED IN RELESSER-PROS REGISTRY

4. AB0594 CLINICAL SIGNIFICANCE OF ANTI-LA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS

6. PO.4.78 Validation analysis of the physician global assessment (PGA) scale in patients with systemic lupus erythematosus included in relesser-pros registry

7. Impact of rheumatoid arthritis on sexuality: adaptation and validation of the Qualisex questionnaire for use in Spain

8. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

9. ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)

10. ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)

12. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER)

13. FACTORS AFFECTING MORTALITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN SPAIN IN THE 21ST CENTURY: DATA FROM THE RELESSER REGISTRY

14. Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study

15. Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?

17. AB0428 ASSOCIATION BETWEEN GEOGRAPHIC AND CLIMATOLOGICAL CONDITIONS AND CUTANEOUS MANIFESTATIONS IN LUPUS PATIENTS FROM THE SPANISH RHEUMATOLOGY SOCIETY LUPUS REGISTRY (RELESSER) AND ARGENTINE RHEUMATOLOGY SOCIETY LUPUS REGISTRY (RELESSAR) COHORT

20. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis

21. HORMONE DEPENDENCE AND CANCER IN SYSTEMIC LUPUS ERYTHEMATOSUS

22. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients

23. Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behcet's Disease: National Multicenter Study of 51 Cases

24. Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project

25. Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease

26. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV; predictive factors of high disease activity over time

27. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV; cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients; results of a nested matched case-control study

29. UTILITY OF APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHCET'S DISEASE

30. Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort

31. Mycobacterial Infection in Systemic Lupus Erythematosus: Clinical Significance and Associated Factors. Data from the Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)

36. FRI0489 Utility of apremilast in refractory oral and/or genital ulcers in behÇet’s disease

37. VALIDATION ANALYSIS OF THE PHYSICIAN GLOBAL ASSESSMENT (PGA) SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS INCLUDED IN RELESSER-PROS REGISTRY.

38. CLINICAL SIGNIFICANCE OF ANTI-LA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS.

39. Impact of Gender in the Quality of Life of Patients with Rheumatoid Arthritis

44. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study

45. Every third patient with new rheumatoid arthritis becomes work disabled in the 2000's:People in poor countries remain working with high levels of disability and disease activity

46. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity

48. Joint pain may be missed in physician assessment of tender joint count

49. [Biopsy of the temporal artery. Experience with the use of a protocol at an ENT department]

50. Physical inactivity in patients with rheumatoid arthritis: Data from twenty-one countries in a cross-sectional, international study

Catalog

Books, media, physical & digital resources